Advances in predicting patient survival in pulmonary sarcoidosis

References

• Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99(5):307–315.
   PubMed Web of Science ®Google Scholar
• Gerke AK. Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med. 2014;20(5):472–478.
   PubMed Web of Science ®Google Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the united states. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Sauer WH, Stern BJ, Baughman RP, et al. High-Risk sarcoidosis. current concepts and research imperatives. Ann Am Thorac Soc. 2017;14(Supplement_6):S437–S444.
   PubMedGoogle Scholar
• Rp B, Lower EE. Features of sarcoidosis associated with chronic disease. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(4):275–281.
   Web of Science ®Google Scholar
• Gupta R, Baughman RP, Sarcoidosis AP. Semin respir crit care med. 2020;41(5):700–715.
   Google Scholar
• Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119(2):167–172.
   PubMed Web of Science ®Google Scholar
• Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275–280.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ee L, Hp LI, et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest. 2017;151(1):139–148.
   PubMed Web of Science ®Google Scholar
• Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–632.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the united states from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–1530.
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Machado RF, Schraufnagel D, et al. Racial difference in sarcoidosis mortality in the united states. Chest. 2014;147(2):438–449.
   Web of Science ®Google Scholar
• Wells AU. Sarcoidosis: a benign disease or a culture of neglect? Respir Med. 2018;144S:S1–S2.
   PubMedGoogle Scholar
• Jamilloux Y, Maucort-Boulch D, Kerever S, et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. 2016;48(6):1700–1709.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003;124(3):922–928.
   PubMed Web of Science ®Google Scholar
• Tukey MH, Berman JS, Boggs DA, et al. Mortality among african american women with sarcoidosis: data from the black women’s health study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):128–133.
   PubMed Web of Science ®Google Scholar
• Kearney GD, Obi ON, Maddipati V, et al. Sarcoidosis deaths in the united states: 1999–2016. Respir Med. 2019;149:30–35.
   PubMed Web of Science ®Google Scholar
• Jeny F, Uzunhan Y, Lacroix M, et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med. 2020;169:105997. Epub@2020 May 12: 105997.
   PubMed Web of Science ®Google Scholar
• Varron L, Cottin V, Schott AM, et al. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore). 2012;91(3):137–143.
   PubMed Web of Science ®Google Scholar
• Rubio-Rivas M, Corbella X, Mana J. Elderly sarcoidosis: a comparative study from a 42-year single-centre experience. Respir Med. 2019;152:1–6. Epub@2019 Mar 26.:1–6.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885–1889.
   PubMed Web of Science ®Google Scholar
• Sawahata M, Sugiyama Y, Nakamura Y, et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015;109(2):272–278.
   PubMed Web of Science ®Google Scholar
• Uzunhan Y, Nunes H, Jeny F, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2017;49(6):49–2016.
   PubMed Web of Science ®Google Scholar
• Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018;153(1):105–113.
   PubMed Web of Science ®Google Scholar
• Rossides M, Kullberg S, Askling J, et al. Sarcoidosis mortality in Sweden: a population-based cohort study. Eur Respir J. 2018;51(2):51–2017.
   PubMed Web of Science ®Google Scholar
• Rabin DL, Thompson B, Brown KM, et al. Sarcoidosis: social predictors of severity at presentation. Eur Respir J. 2004;24(4):601–608.
   PubMed Web of Science ®Google Scholar
• Harper LJ, Gerke AK, Wang XF, et al. Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. Am J Respir Crit Care Med. 2020;201(8):955–964.
   PubMed Web of Science ®Google Scholar
• Je G, Hl I, Rm S, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004;169(6):696–702.
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739.
   PubMed Web of Science ®Google Scholar
• Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37(4):357–364.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wei J, Fan L, et al. BTNL2 gene polymorphism and sarcoidosis susceptibility: a meta-analysis. PLoS ONE. 2015;10(4):e0122639.
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Walewski JL, Maliarik MJ, et al. The BTNL2 gene and sarcoidosis susceptibility in african americans and whites. Am J Hum Genet. 2005;77(3):491–499.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Sato H, Grutters JC, et al. Analysis of BTNL2 genetic polymorphisms in british and dutch patients with sarcoidosis. Tissue Antigens. 2007;70(3):219–227.
   PubMedGoogle Scholar
• Wijnen PA, Voorter CE, Nelemans PJ, et al. Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression? Hum Immunol. 2011;72(4):342–347.
   PubMed Web of Science ®Google Scholar
• Morais A, Lima B, Alves H, et al. Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles. Clin Respir J. 2018;12(2):532–537.
   PubMed Web of Science ®Google Scholar
• Pacheco Y, Calender A, Israel-Biet D, et al. Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort. Orphanet J Rare Dis. 2016;11(1):165–0546.
   PubMedGoogle Scholar
• Sato H, Williams HR, Spagnolo P, et al. CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. Eur Respir J. 2010;35(2):324–330.
   PubMed Web of Science ®Google Scholar
• Heron M, Van Moorsel CH, Grutters JC, et al. Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens. 2011;77(2):112–117.
   PubMedGoogle Scholar
• Kruit A, Grutters JC, Ruven HJ, et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest. 2006;129(6):1584–1591.
   PubMed Web of Science ®Google Scholar
• Hill MR, Papafili A, Booth H, et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med. 2006;174(8):915–922.
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Acar-Denizli N, Siso-Almirall A, et al. The burden of comorbidity and complexity in sarcoidosis: impact of associated chronic diseases. Lung. 2018;196(2):239–248.
   PubMed Web of Science ®Google Scholar
• Nowinski A, Puscinska E, Goljan A, et al. The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. Clin Respir J. 2017;11(5):648–656.
   PubMed Web of Science ®Google Scholar
• Yafasova A, Fosba¸l EL, Schou M, et al. Long-term adverse cardiac outcomes in patients with sarcoidosis. J Am Coll Cardiol. 2020;76(7):767–777.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J. 2017;49(2):2016–13993003.
   Web of Science ®Google Scholar
• Ungprasert P, Wijarnpreecha K, Cheungpasitporn W, et al. Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: nationwide Inpatient Sample 2013–2014. Lung. 2019;197(2):165–171.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Rosi E, Pistolesi M, et al. Increased Risk of Atherosclerosis in Patients with Sarcoidosis. Pathobiology. 2017;84(5):258–263.
   PubMed Web of Science ®Google Scholar
• Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;208:525–533.
   Google Scholar
• Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995;50(5):555–559.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis. 1996;13:167–172.
   Google Scholar
• Rodrigues SC, Rocha NA, Lima MS, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):34–43.
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–2165.
   PubMed Web of Science ®Google Scholar
• Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115(4):1158–1165.
   PubMed Web of Science ®Google Scholar
• Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration. 1994;61(4):219–225.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis. 1994;11(2):123–130.
   PubMedGoogle Scholar
• Judson MA, Preston S, Hu K, et al. Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. Respir Med. 2019;152:14–19. Epub@2019 Mar 23.:14–19.
   PubMed Web of Science ®Google Scholar
• Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 1998;15:52–58.
   Google Scholar
• Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):90–98.
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):29–292019.
   Web of Science ®Google Scholar
• Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis. 1997;14:154–158.
   Google Scholar
• Te K Jr., Safrin S, Km S, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005;127(1):171–177.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435.
   PubMed Web of Science ®Google Scholar
• Taha N, D’Amato D, Hosein K, et al. Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters? Respir Res. 2020;21(1):119–01371.
   PubMed Web of Science ®Google Scholar
• Kouranos V, Ward S, Kokosi MA, et al. Mixed Ventilatory Defects in Pulmonary Sarcoidosis: prevalence and Clinical Features. Chest. 2020;158(5):2007–2014.
   PubMed Web of Science ®Google Scholar
• Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516–522.
   PubMed Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;4(5261):1165–1172.
   Google Scholar
• Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull. 1982;29(1):27–32.
   PubMedGoogle Scholar
• Pietinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:158–166.
   PubMed Web of Science ®Google Scholar
• Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest. 2002 Jan;121(1):32–39.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014;2(2):123–130.
   PubMed Web of Science ®Google Scholar
• Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging. 1999;14(4):270–278.
   PubMed Web of Science ®Google Scholar
• Devaraj A, Wells AU, Meister MG, et al. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology. 2008;249(3):1042–1049.
   PubMed Web of Science ®Google Scholar
• Zisman DA, Karlamangla AS, Ross DJ, et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2007;132(3):773–779.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(2):108–116.
   PubMed Web of Science ®Google Scholar
• Huitema MP, Spee M, Vorselaars VM, et al. Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur Respir J. 2016;47(2):673–676.
   PubMed Web of Science ®Google Scholar
• Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.
   PubMed Web of Science ®Google Scholar
• Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–969.
   PubMed Web of Science ®Google Scholar
• Gangemi AJ, Myers CN, Zheng M, et al. Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center. Respir Med. 2019;157:69–76.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078–1085.
   PubMed Web of Science ®Google Scholar
• Shlobin OA, Kouranos V, Barnett SD, et al. Physiological predictors of survival in patients with sarcoidosis associated pulmonary hypertension: results from an international registry. Eur Respir J. 2020;55(5):1901747–1902019.
   PubMed Web of Science ®Google Scholar
• Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50(4):50–2017.
   Web of Science ®Google Scholar
• Tiosano S, Versini M, Dar AL, et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study. Clin Immunol. 2019;199:57–61.
   PubMed Web of Science ®Google Scholar
• Bonham CA, Oldham JM, Gomberg-Maitland M, et al. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015;148(4):1055–1062.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Shlobin OA, Wells AU, et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med. 2018;139:72–78.
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Omar HR, Baughman R, et al. The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(4):317–320.
   PubMed Web of Science ®Google Scholar
• Arun J, Joseph D, Jonathan G, et al. Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(4):308–316.
   PubMed Web of Science ®Google Scholar
• Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(10):1150–1157.
   PubMed Web of Science ®Google Scholar
• Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084–1090.
   PubMed Web of Science ®Google Scholar
• Cj L, Sd N, Rf B, et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100(10):1734–1741.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med. 2007;13(5):439–444.
   PubMed Web of Science ®Google Scholar
• Rp B, Bk S, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132(1):207–213.
   PubMed Web of Science ®Google Scholar
• Alhamad EH. The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med. 2009;4(2):60–64.
   PubMed Web of Science ®Google Scholar
• Alhamad EH, Idrees MM, Alanezi MO, et al. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in arab patients. Ann Thorac Med. 2010;5(2):86–91.
   PubMed Web of Science ®Google Scholar
• Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32(2):296–302.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–e51.
   PubMed Web of Science ®Google Scholar
• Shlobin OA, Baughman RP. Sarcoidosis-associated pulmonary hypertension. Semin Respir Crit Care Med. 2017;38(4):450–462.
   PubMed Web of Science ®Google Scholar
• Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128(3):1483–1489.
   PubMed Web of Science ®Google Scholar
• Huitema MP, Grutters JC, Bjwm R, et al. Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J. 2016;24(6):390–399.
   PubMed Web of Science ®Google Scholar
• York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011;23(6):536–544.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–975.
   PubMed Web of Science ®Google Scholar
• Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167–172.
   PubMed Web of Science ®Google Scholar
• Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J. 2013;41(3):621–626.
   PubMed Web of Science ®Google Scholar
• Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol. 2011;49(2):198–201.
   PubMed Web of Science ®Google Scholar
• Lejay A, Falcoz PE, Santelmo N, et al. Surgery for aspergilloma: time trend towards improved results? Interact Cardiovasc Thorac Surg. 2011;13(4):392–395.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Vishwanath G, Aggarwal AN, et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses. 2013;56(5):559–570.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET positive sarcoidosis. Eur Respir J. 2015;46(1):175–185.
   PubMed Web of Science ®Google Scholar
• Schimmelpennink MC, Vorselaars ADM, Van Beek FT, et al. Efficacy and safety of infliximab biosimilar Inflectra((R)) in severe sarcoidosis. Respir Med. 2018;138S:S7–S13.
   PubMedGoogle Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung. 2017;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Guleria R, Jyothidasan A, Madan K, et al. Utility of FDG-PET-CT scanning in assessing the extent of disease activity and response to treatment in sarcoidosis. Lung India. 2014;31(4):323–330.
   PubMedGoogle Scholar
• Mostard RL, Voo S, Van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105(12):1917–1924.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J. 2013;41(6):1424–1438.
   PubMed Web of Science ®Google Scholar
• James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11;677–687.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Lower EE, Sturdivant M, Grate L et al. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol. 2019;38(5):834–840.
   PubMed Web of Science ®Google Scholar
• Nj S, Ee L, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Rotenberg C, Besnard V, Brillet PY, et al. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6):2018–13993003.
   Web of Science ®Google Scholar
• Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011;38(6):1368–1373.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):10.
   Web of Science ®Google Scholar
• Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014;145(4):810–817.
   PubMed Web of Science ®Google Scholar